The innate immune response to secondary peritonitis

Shock

Volumn 28, Issue 5, 2007, Pages 504-517

  Van Till, J W Olivier ^a   Van Veen, Suzanne Q ^a   Van Ruler, Oddeke ^a   Lamme, Bas ^a   Gouma, Dirk J ^a   Boermeester, Marja A ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Abdominal sepsis; Host defense; Immune response; Inflammation; Pathophysiology; Peritonitis

Indexed keywords

APC PROTEIN; CD18 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; COMPLEMENT COMPONENT C5A; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; MACROPHAGE DERIVED CHEMOKINE; MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PHOSPHOLIPASE A2; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

BLOOD CLOTTING; CELL ADHESION; CELL MIGRATION; CHEMOTAXIS; DISEASE SEVERITY; FIBRINOLYSIS; HOST RESISTANCE; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; MORTALITY; NONHUMAN; PERITONITIS; PROTEIN EXPRESSION; REVIEW; SEPSIS; TISSUE INJURY;

BACTERIAL INFECTIONS; BLOOD COAGULATION; CHEMOTAXIS; COMPLEMENT ACTIVATION; DOWN-REGULATION; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTES; LUNG; MULTIPLE ORGAN FAILURE; ORGAN SPECIFICITY; PERITONITIS; PROGNOSIS;

EID: 37349025749     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/shk.0b013e318063e6ca     Document Type: Review

References (172)

1. Evans HL, Raymond DP, Pelletier SJ, Crabtree TD, Pruett TL, Sawyer RG: Diagnosis of intra-abdominal infection in the critically ill patient. Curr Opin Crit Care 7:117-121, 2001.
2. Lamme B, Boermeester MA, Belt EJ, Van Till JWO, Gouma DJ, Obertop H: Mortality and morbidity of planned relaparotomy versus relaparotomy on demand for secondary peritonitis. Br J Surg 91:1046-1054, 2004.
3. Koperna T, Schulz F: Prognosis and treatment of peritonitis. Do we need new scoring systems? Arch Surg 131:180-186, 1996.
4. Farthmann EH, Schoffel U: Epidemiology and pathophysiology of intra-abdominal infections (IAI). Infection 26:329-334, 1998.
5. Hall JC, Heel KA, Papadimitriou JM, Platell C: The pathobiology of peritonitis. Gastroenterology 114:185-196, 1998.
6. Cailhier JF, Partolina M, Vuthoori S, Wu S, Ko K, Watson S, Savill J, Hughes J, Lang RA: Conditional macrophage ablation demonstrates that resident macrophages initiate acute peritoneal inflammation. J Immunol 174:2336-2342, 2005.
7. Broche F, Tellado JM: Defense mechanisms of the peritoneal cavity. Curr Opin Crit Care 7:105-116, 2001.
8. Rittirsch D, Hoesel LM, Ward PA: The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 81:137-143, 2007.
9. Moldawer LL, Gelin J, Schersten T, Lundholm KG: Circulating interleukin 1 and tumor necrosis factor during inflammation. Am J Physiol 253:R922-R928, 1987.
10. Echtenacher B, Falk W, Mannel DN, Krammer PH: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145:3762-3766, 1990.
11. Rios-Santos F, Benjamim CF, Zavery D, Ferreira SH, Cunha FD: A critical role of leukotriene B-4 in neutrophil migration to infectious focus in cecal ligation and puncture sepsis. Shock 19:61-65, 2003.
12. Abe T, Sakamoto K, Mita S, Kamohara H, Hirano YI, Kuwahara N, Ogawa M: Surgical trauma induces group II phospholipase A2 production by neutrophils at a local site after surgery. Clin Biochem 31:101-106, 1998.
13. Laine VJO, Grass DS, Nevalainen TJ: Resistance of transgenic mice expressing human group II phospholipase A2 to Escherichia coli infection. Infect Immun 68:87-92, 2000.
14. Call DR, Nemzek JA, Ebong SJ, Bolgos GL, Newcomb DE, Remick DG: Ratio of local to systemic chemokine concentrations regulates neutrophil recruitment. Am J Pathol 158:715-721, 2001.
15. Sendt W, Wolff-Vorbeck G, Leipziger J, von Specht BU, Schoffel U: In vitro peritonitis: basic inflammatory reactions in a two-chamber co-culture model of human peritoneum. Int J Colorect Dis 15:229-235, 2000.
16. Betjes MG, Tuk CW, Struijk DG, Krediet RT, Arisz L, Hart M, Beelen RH: Interleukin-8 production by human peritoneal mesothelial cells in response to tumor necrosis factor-alpha, interleukin-1, and medium conditioned by macrophages cocultured with Staphylococcus epidermidis. J Infect Dis 168:1202-1210, 1993.
17. Wellmer A, Gerber J, Ragheb J, Zysk G, Kunst T, Smirnov A, Bruck W, Nau R: Effect of deficiency of tumor necrosis factor alpha or both of its receptors on Streptococcus pneumoniae central nervous system infection and peritonitis. Infect Immun 69:6881-6886, 2001.
18. Visser CE, Tekstra J, Brouwer-Steenbergen JJ, Tuk CW, Boorsma DM, Sampat-Sardjoepersad SC, Meijer S, Krediet RT, Beelen RH: Chemokines produced by mesothelial cells: huGRO-alpha, IP-10, MCP-1 and RANTES. Clin Exp Immunol 112:270-275, 1998.
19. Ajuebor MN, Das AM, Virag L, Flower RJ, Szabo C, Perretti M: Role of resident peritoneal macrophages and mast cells in chemokine production and neutrophil migration in acute inflammation: evidence for an inhibitory loop involving endogenous IL-10. J Immunol 162:1685-1691, 1999.
20. Mercer-Jones MA, Shrotri MS, Heinzelmann M, Peyton JC, Cheadle WG: Regulation of early peritoneal neutrophil migration by macrophage inflammatory protein-2 and mast cells in experimental peritonitis. J Leukoc Biol 65:249-255, 1999.
21. Ajuebor MN, Das AM, Virag L, Szabo C, Perretti M: Regulation of macrophage inflammatory protein-1 alpha expression and function by endogenous interleukin-10 in a model of acute inflammation. Biochem Biophys Res Commun 255:279-282, 1999.
22. Montravers P, Maulin L, Mohler, Carbon C: Microbiological and inflammatory effects of murine recombinant interleukin-10 in two models of polymicrobial peritonitis in rats. Infect Immun 67:1579-1584, 1999.
23. Sewnath ME, Olszyna DP, Birjmohun R, ten Kate FJW, Gouma DJ, van der Poll T: IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J Immunol 166:6323-6331, 2001.
24. Hori Y, Nihei Y, Kurokawa Y, Kuramasu A, Makabe-Kobayashi Y, Terui T, Doi H, Satomi S, Sakurai E, Nagy A, et al.: Accelerated clearance of Escherichia coli in experimental peritonitis of histamine-deficient mice. J Immunol 169:1978-1983, 2002.
25. Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Evanoff HL, Strieter RM, Kunkel SL: Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J Immunol 164:2738-2744, 2000.
26. Van Leeuwen PA, Boermeester MA, Houdijk AP, Ferwerda CC, Cuesta MA, Meyer S, Wesdorp RI: Clinical significance of translocation. Gut 35:S28-S34, 1994.
27. van Mourik JA, de Wit TR, Voorberg: Biogenesis and exocytosis of Weibel-Palade bodies. Histochem Cell Biol 117:113-122, 2002.
28. Kobayashi A, Hashimoto S, Kooguchi K, Kitamura Y, Onodera H, Urata Y, Ashihara T: Expression of inducible nitric oxide synthase and inflammatory cytokines in alveolar macrophages of ARDS following sepsis. Chest 113:1632-1639, 1998.
29. Tsujimoto H, Ono S, Majima T, Kawarabayashi N, Takayama E, Kinoshita M, Seki S, Hiraide H, Moldawer LL, Mochizuki H: Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis. Shock 23:39-44, 2005.
30. Holzer K, Schubel F, Konietzny P, Wilhelm K, Bechstein WO, Henrich D: Interleukin 8 mRNA gene expression in peripheral and intra-abdominal neutrophils during human secondary peritonitis. Shock 23:501-506, 2005.
31. Neumann B, Zantl N, Veihelmann A, Emmanuilidis K, Pfeffer K, Heidecke CD, Holzmann B: Mechanisms of acute inflammatory lung injury induced by abdominal sepsis. Int Immunol 11:217-227, 1999.
32. Mercer-Jones MA, Shrotri MS, Peyton JC, Remick DG, Cheadle WG: Neutrophil sequestration in liver and lung is differentially regulated by C-X-C chemokines during experimental peritonitis. Inflammation 23:305-319, 1999.
33. Tighe D, Moss R, Parker-Williams J, Hynd J, Bennett ED: A phospholipase inhibitor modifies the pulmonary damage associated with peritonitis in rabbits. Intensive Care Med 13:284-290, 1987.
34. Maier S, Emmanuilidis K, Entleutner M, Zantl N, Werner M, Pfeffer K, Heidecke CD: Massive chemokine transcription in acute renal failure due to polymicrobial sepsis. Shock 14:187-192, 2000.
35. Wickel DJ, Mercer-Jones M, Peyton JC, Shrotri MS, Cheadle WG: Neutrophil migration into the peritoneum is P-selectin dependent, but sequestration in lungs is selectin independent during peritonitis. Shock 10:265-269, 1998.
36. Bauer P, Lush CW, Kvietys PR, Russell JM, Granger DN: Role of endotoxin in the expression of endothelial selectins after cecal ligation and perforation. Am J Physiol 278:R1140-R1147, 2000.
37. Lush CW, Cepinskas G, Sibbald WJ, Kvietys PR: Endothelial E-and P-selectin expression in iNOS-deficient mice exposed to polymicrobial sepsis. Am J Physiol 280:G291-G297, 2001.
38. Bullard DC, Qin L, Lorenzo I, Quinlin WM, Doyle NA, Bosse R, Vestweber D, Doerschuk CM, Beaudet AL: P-selectin/ICAM-1 double mutant mice: acute emigration of neutrophils into the peritoneum is completely absent but is normal into pulmonary alveoli. J Clin Invest 95:1782-1788, 1995.
39. Guo RF, Riedemann NC, Laudes IJ, Sarma VJ, Kunkel RG, Dilley KA, Paulauskis JD, Ward PA: Altered neutrophil trafficking during sepsis. J Immunol 169:307-314, 2002.
40. Gardinali M, Borrelli E, Chiara O, Lundberg C, Padalino P, Conciato L, Cafaro C, Lazzi S, Luzi P, Giomarelli PP, et al.: Inhibition of CD11-CD18 complex prevents acute lung injury and reduces mortality after peritonitis in rabbits. Am J Respir Crit Care Med 161:1022-1029, 2000.
41. Jonjic N, Peri G, Bernasconi S, Sciacca FL, Colotta F, Pelicci P, Lanfrancone L, Mantovani A: Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med 176:1165-1174, 1992.
42. Crockett ET, Remelius C, Hess K, Al Ghawi H: Gene deletion of P-Selectin and ICAM-1 does not inhibit neutrophil infiltration into peritoneal cavity following cecal ligation-puncture. BMC Clin Pathol 4:2, 2004.
43. Heuer JG, Sharma GR, Gerlitz B, Zhang T, Bailey DL, Ding C, Berg DT, Perkins D, Stephens EJ, Holmes KC, et al.: Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit Care Med 32:1570-1578, 2004.
44. Enoh VT, Fairchild CD, Lin CY, Varma TK, Sherwood ER: Differential effect of imipenem treatment on wild-type and NK cell-deficient CD8 knockout mice during acute intra-abdominal injury. Am J Physiol Regul Integr Comp Physiol 290:R685-R693, 2006.
45. Dalrymple SA, Slattery R, Aud DM, Krishna M, Lucian LA, Murray R: Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect Immun 64:3231-3235, 1996.
46. Weijer S, Florquin S, van der Poll T: Endogenous interleukin-12 improves the early antimicrobial host response to murine Escherichia coli peritonitis. Shock 23:54-58, 2005.
47. Moreno SE, Alves-Filho JC, Alfaya TM, da Silva JS, Ferreira SH, Liew FY: IL-12, but not IL-18, is critical to neutrophil activation and resistance to polymicrobial sepsis induced by cecal ligation and puncture. J Immunol 177:3218-3224, 2006.
48. Zisman DA, Kunkel SL, Strieter RM, Gauldie J, Tsai WC, Bramson J, Wilkowski JM, Bucknell KA, Standiford TJ: Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis. Shock 8:349-356, 1997.
49. Steinhauser ML, Hogaboam CM, Lukacs NW, Strieter RM, Kunkel SL: Multiple roles for IL-12 in a model of acute septic peritonitis. J Immunol 162:5437-5443, 1999.
50. Seki S, Osada S, Ono S, Aosasa S, Habu Y, Nishikage T, Mochizuki H, Hiraide H: Role of liver NK cells and peritoneal macrophages in gamma interferon and interleukin-10 production in experimental bacterial peritonitis in mice. Infect Immun 66:5286-5294, 1998.
51. Godshall CJ, Scott MJ, Burch PT, Peyton JC, Cheadle WG: Natural killer cells participate in bacterial clearance during septic peritonitis through interactions with macrophages. Shock 19:144-149, 2003.
52. Weijer S, Sewnath ME, de Vos AF, Florquin S, van der Sluis K, Gouma DJ, Takeda Y, Akira S, van der Poll T: Interleukin-18 facilitates the early antimicrobial host response to Escherichia coli peritonitis. Infect Immun 71: 5488-5497, 2003.
53. Root RK, Dale DC: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 179(Suppl 2):342-352, 1999.
54. Attalah HL, Azoulay E, Yang K, Lasclos C, Jouault H, Soussy CJ, Guillot T, Brochard L, Brun-Buisson C, Harf A, et al.: Granulocyte colony-stimulating factor enhances host defenses against bacterial pneumonia following peritonitis in nonneutropenic rats. Crit Care Med 30:2107-2114, 2002.
55. Villa P, Shaklee CL, Meazza C, Agnello D, Ghezzi P, Senaldi G: Granulocyte colony-stimulating factor and antibiotics in the prophylaxis of a murine model of polymicrobial peritonitis and sepsis. J Infect Dis 178:471-477, 1998.
56. Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, Schmal H, Friedl HP, Ward PA: Protective effects of C5a blockade in sepsis. Nat Med 5:788-792, 1999.
57. Celik I, Stover C, Botto M, Thiel S, Tzima S, Kunkel D, Walport M, Lorenz W, Schwaeble W: Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis. Infect Immun 69:7304-7309, 2001.
58. Windbichler M, Echtenacher B, Hehlgans T, Jensenius JC, Schwaeble W, Mannel DN: Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis. Infect Immun 72:5247-5252, 2004.
59. Wirtz S, Tubbe I, Galle PR, Schild HJ, Birkenbach M, Blumberg RS, Neurath MF: Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J Exp Med 203:1875-1881, 2006.
60. Turnbull IR, Javadi P, Buchman TG, Hotchkiss RS, Karl IE, Coopersmith CM: Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 21:121-125, 2004.
61. Vianna RC, Gomes RN, Bozza FA, Amancio RT, Bozza PT, David CM, Castro-Faria-Neto HC: Antibiotic treatment in a murine model of sepsis: impact on cytokines and endotoxin release. Shock 21:115-120, 2004.
62. Mercer-Jones MA, Hadjiminas DJ, Heinzelmann M, Peyton J, Cook M, Cheadle WG: Continuous antibiotic treatment for experimental abdominal sepsis: effects on organ inflammatory cytokine expression and neutrophil sequestration. Br J Surg 85:385-389, 1998.
63. Holzheimer RG: Antibiotic induced endotoxin release and clinical sepsis: a review. J Chemother 13(Spec No 1):159-172, 2001.
64. Moon DK, Geczy CL. Recombinant IFN-gamma synergizes with lipopolysaccharide to induce macrophage membrane procoagulants. J Immunol 141:1536-1542, 1988.
65. Zuckerman SH, Suprenant YM: Induction of endothelial cell/macrophage procoagulant activity: synergistic stimulation by gamma interferon and granulocyte-macrophage colony stimulating factor. Thromb Haemost 61:178-182, 1989.
66. Marshall JC: Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 29:S99-S106, 2001.
67. Qiu G, Gribbin E, Harrison K, Sinha N, Yin K: Inhibition of gamma interferon decreases bacterial load in peritonitis by accelerating peritoneal fibrin deposition and tissue repair. Infect Immun 71:2766-2774, 2003.
68. Renckens R, Roelofs JJ, Florquin S, de Vos AF, Pater JM, Lijnen HR, Carmeliet P, van't Veer C, van der Poll T: Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice. J Immunol 177:1189-1196, 2006.
69. Ahrenholz DH, Simmons RL: Fibrin in peritonitis. I. Beneficial and adverse effects of fibrin in experimental E. coli peritonitis. Surgery 88:41-47, 1980.
70. Echtenacher B, Weigl K, Lehn N, Mannel DN: Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect Immun 69:3550-3555, 2001.
71. Fry DE, Garrison RN, Heitsch RC, Calhoun K, Polk HC Jr: Determinants of death in patients with intra-abdominal abscess. Surgery 88:517-523, 1980.
72. Levi M, ten Cate H: Current concepts - disseminated intravascular coagulation. N Engl J Med 341:586-592, 1999.
73. Van Goor H, Bom VJJ, van der Meer J, Sluiter WJ, Bleichrodt RP: Coagulation and fibrinolytic responses of human peritoneal fluid and plasma to bacterial peritonitis. Br J Surg 83:1133-1135, 1996.
74. Van Till JWO, Levi M, Bresser P, Schultz MJ, Gouma DJ, Boermeester MA: Early procoagulant shift in the bronchoalveolar compartment of patients with secondary peritonitis. J Infect Dis 1:1331-1339, 2006.
75. Van Goor H, de Graaf JS, Grond J, Sluiter WJ, van der Meer J, Bom VJJ, Bleichrodt RP: Fibrinolytic activity in the abdominal cavity of rats with fecal peritonitis. Br J Surg 81:1046-1049, 1994.
76. Mandl-Weber S, Haslinger B, Lederer SR, Sitter T: Heat-killed microorganisms induce PAI-1 expression in human peritoneal mesothelial cells: role of interleukin-1 alpha. Am J Kidney Dis 37:815-819, 2001.
77. Tietze L, Elbrecht A, Schauerte C, Klosterhalfen B, Amo-Takyi B, Gehlen J, Winkeltau G, Mittermayer C, Handt S: Modulation of pro-and antifibrinolytic properties of human peritoneal mesothelial cells by transforming growth factor beta(1) (TGF-beta(1)), tumor necrosis factor alpha (TNF-alpha) and interleukin 1 beta (IL-1 beta). Thromb Haemost 79:362-370, 1998.
78. Whawell SA, Vipond MN, Scottcoombes DM, Thompson JN: Plasminogen activator inhibitor 2 reduces peritoneal fibrinolytic activity in inflammation. Br J Surg 80:107-109, 1993.
79. Holmdahl L, Eriksson E, Al Jabreen M, Risberg B: Fibrinolysis in human peritoneum during operation. Surgery 119:701-705, 1996.
80. Wickel DJ, Cheadle WG, Mercer-Jones MA, Garrison RN: Poor outcome from peritonitis is caused by disease acuity and organ failure, not recurrent peritoneal infection. Ann Surg 225:744-753, 1997.
81. Slotwinski R, Olszewski WL, Chaber A, Slodkowski M, Zaleska M, Krasnodebski IW: The soluble tumor necrosis factor receptor I is an early predictor of local infective complications after colorectal surgery. J Clin Immunol 22:289-296, 2002.
82. Herwig R, Glodny B, Kuhle C, Schluter B, Brinkmann OA, Strasser H, Senninger N, Winde G: Early identification of peritonitis by peritoneal cytokine measurement. Dis Colon Rectum 45:514-521, 2002.
83. Berge Henegouwen MI, van der Poll T, van Deventer SJ, Gouma DJ: Peritoneal cytokine release after elective gastrointestinal surgery and post-operative complications. Am J Surg 175:311-316, 1998.
84. Holzer K, Richter A, Konietzny P, Schubel F, Wilhelm K, Henrich D: Untersuchungen zu Funktionen zirkulierender und intraabdominaler polymorphkerniger Leukozyten bei Patienten mit sekundärer Peritonitis. Zentralbl Chir 128:291-297, 2003.
85. Fröhlich D, Eiber RM, Jochum M, Billing A: Perioperative pattern of peritoneal interleukin 8, tumour necrosis factor-alpha, and granulocyte elastase release in human secondary peritonitis. Cytokine 9:288-292, 1997.
86. Van Till JWO, Lamme B, van Esch TJ, van der Poll T, van Gulik TM, Boermeester MA: Surgical therapy attenuates abdominal and extra-abdominal inflammation in experimental peritonitis. Eur Surg Res 38:76-82, 2006.
87. Függer R, Zadrobilek E, Gotzinger P, Klimann S, Rogy M, Winkler S, Andel H, Mittelbock M, Roth E, Schulz F: Perioperative TNF alpha and IL-6 concentrations correlate with septic state, organ function, and APACHE II scores in intra-abdominal infection. Eur J Surg 159:525-529, 1993.
88. Tang GJ, Kuo CD, Yen TC, Kuo HS, Chan KH, Yien HW, Lee TY: Perioperative plasma concentrations of tumor necrosis factor-alpha and interleukin-6 in infected patients. Crit Care Med 24:423-428, 1996.
89. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 13:818-829, 1985.
90. Holzheimer RG, Schein M, Wittmann DH: Inflammatory response in peritoneal exudate and plasma of patients undergoing planned relaparotomy for severe secondary peritonitis. Arch Surg 130:1314-1319, 1995.
91. Burger JA, Schoffel U, Sach M, Jacobs E, Kownatzki E, von Specht BU, Farthmann EH: Effects of peritonitis exudates on chemotaxis and phagocytosis of human neutrophils. Eur J Surg 161:647-653, 1995.
92. Holzer K, Richter A, Henrich D, Wilhelm K, Encke A: Oxygen radical generation by emigrated, intra-abdominal, and circulating PMNLs during human secondary peritonitis. Shock 15:90-94, 2001.
93. Schröder J, Staubach KH, Zabel P, Stuber F, Kremer B: Procalcitonin as a marker of severity in septic shock. Langenbecks Arch Surg 384:33-38, 1999.
94. Reith HB, Mittelkotter U, Debus ES, Kussner C, Thiede A: Procalcitonin in early detection of postoperative complications. Dig Surg 15:260-265, 1998.
95. Van der Poll T, Marchant A, Buurman WA, Berman L, Keogh CV, Lazarus DD, Nguyen L, Goldman M, Moldawer LL, Lowry SF: Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 155:5397-5401, 1995.
96. Rongione AJ, Kusske AM, Ashley SW, Reber HA, McFadden DW: Interleukin-10 prevents early cytokine release in severe intra-abdominal infection and sepsis. J Surg Res 70:107-112, 1997.
97. Latifi SQ, O'Riordan MA, Levine AD: Interleukin-10 controls the onset of irreversible septic shock. Infect Immun 70:4441-4446, 2002.
98. Scott MJ, Hoth JJ, Turina M, Woods DR, Cheadle WG: Interleukin-10 suppresses natural killer cell but not natural killer T cell activation during bacterial infection. Cytokine 33:79-86, 2006.
99. Rongione AJ, Kusske AM, Kwan K, Ashley SW, Reber HA, McFadden DW: Interleukin-10 protects against lethality of intra-abdominal infection and sepsis. J Gastrointest Surg 4:70-76, 2000.
100. Ferrer TJ, Webb JW, Wallace BH, Bridges CD, Palmer HE, Robertson RD, Cone JB: Interleukin-10 reduces morbidity and mortality in murine multiple organ dysfunction syndrome (MODS). J Surg Res 77:157-164, 1998.
101. Jansen MJ, Hendriks T, Hermsen R, van der Meer JW, Goris RJ: A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome. Cytokine 10:904-910, 1998.
102. Kohler J, Heumann D, Garotta G, LeRoy D, Bailat S, Barras C, Baumgartner JD, Glauser MP: IFN-gamma involvement in the severity of gram-negative infections in mice. J Immunol 151:916-921, 1993.
103. Yin K, Gribbin E, Wang H: Interferon-gamma inhibition attenuates lethality after cecal ligation and puncture in rats: implication of high mobility group box-1. Shock 24:396-401, 2005.
104. Zantl N, Uebe A, Neumann B, Wagner H, Siewert JR, Holzmann B, Heidecke CD, Pfeffer K: Essential role of gamma interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect Immun 66:2300-2309, 1998.
105. Entleutner M, Traeger T, Westerholt A, Holzmann B, Stier A, Pfeffer K, Maier S, Heidecke CD: Impact of interleukin-12, oxidative burst, and iNOS on the survival of murine fecal peritonitis. Int J Colorectal Dis 21:64-70, 2006.
106. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836-1843, 1994.
107. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, et al.: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 351:929-933, 1998.
108. Lorenz W, Reimund KP, Weitzel F, Celik I, Kurnatowski M, Schneider C, Mannheim W, Heiske A, Neumann K, Sitter H: Granulocyte colony-stimulating factor prophylaxis before operation protects against lethal consequences of postoperative peritonitis. Surgery 116:925-934, 1994.
109. O'Reilly M, Silver GM, Greenhalgh DG, Gamelli RL, Davis JH, Hebert JC: Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma 33:679-682, 1992.
110. Barsig J, Bundschuh DS, Hartung T, Bauhofer A, Sauer A, Wendel A: Control of fecal peritoneal infection in mice by colony-stimulating factors. J Infect Dis 174:790-799, 1996.
111. Echtenacher B, Freudenberg MA, Jack RS, Mannel DN: Differences in innate defense mechanisms in endotoxemia and polymicrobial septic peritonitis. Infect Immun 69:7271-7276, 2001.
112. Ono S, Ueno C, Aosasa S, Tsujimoto H, Seki S, Mochizuki H: Severe sepsis induces deficient interferon-gamma and interleukin-12 production, but interleukin-12 therapy improves survival in peritonitis. Am J Surg 182:491-497, 2001.
113. Calandra T, Echtenacher B, Le Roy D, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164-170, 2000.
114. Pollak N, Sterns T, Echtenacher B, Mannel DN: Improved resistance to bacterial superinfection in mice by treatment with macrophage migration inhibitory factor. Infect Immun 73:6488-6492, 2005.
115. Wang SC, Klein RD, Wahl WL, Alarcon WH, Garg RJ, Remick DG, Su GL: Tissue coexpression of LBP and CD14 mRNA in a mouse model of sepsis. J Surg Res 76:67-73, 1998.
116. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, et al.: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101: 296-301, 2004.
117. Karamarkovic A, Radenkovic D, Milic N, Bumbasirevic V, Stefanovic B: Protein C as an early marker of severe septic complications in diffuse secondary peritonitis. World J Surg 29:759-765, 2005.
118. Prodeus AP, Zhou XN, Maurer M, Galli SJ, Carroll MC: Impaired mast cell-dependent natural immunity in complement C3-deficient mice. Nature 390:172-175, 1997.
119. Gommerman JL, Oh DY, Zhou XN, Tedder TF, Maurer M, Galli SJ, Carroll MC: A role for CD21/CD35 and CD19 in responses to acute septic peritonitis: a potential mechanism for mast cell activation. J Immunol 165:6915-6921, 2000.
120. Boes M, Prodeus AP, Schmidt T, Carroll MC, Chen JZ: A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med 188:2381-2386, 1998.
121. Takahashi K, Gordon J, Liu H, Sastry KN, Epstein JE, Motwani M, Laursen I, Thiel S, Jensenius JC, Carroll MC, et al.: Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis. Microbes Infect 4:773-784, 2002.
122. Garred P, Strom JJ, Quist L, Taaning E, Madsen HO: Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J Infect Dis 188:1394-1403, 2003.
123. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771-778, 1993.
124. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV, Lambris JD, Ward PA: Protective effects of IL-6 blockade in sepsis are linked to reduced c5a receptor expression. J Immunol 170:503-507, 2003.
125. Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S: Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 115:2444-2453, 2005.
126. Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Evanoff HL, Kunkel SL: Pivotal role of the CC chemokine, macrophage-derived chemokine, in the innate immune response. J Immunol 164:5362-5368, 2000.
127. Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Strieter RM, Kunkel SL: Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B-4. J Immunol 163:6148-6154, 1999.
128. Steinhauser ML, Hogaboam CM, Matsukawa A, Lukacs NW, Strieter RM, Kunkel SL: Chemokine C10 promotes disease resolution and survival in an experimental model of bacterial sepsis. Infect Immun 68:6108-6114, 2000.
129. Riese J, Schoolmann S, Denzel C, Herrmann O, Hohenberger W, Haupt W: Effect of abdominal infections on peritoneal and systemic production of interleukin 6 and monocyte chemoattractant protein-1. Shock 17:361-364, 2002.
130. Scott MJ, Cheadle WG, Hoth JJ, Peyton JC, Subbarao K, Shao WH, Haribabu B: Leukotriene B4 receptor (BLT-1) modulates neutrophil influx into the peritoneum but not the lung and liver during surgically induced bacterial peritonitis in mice. Clin Diagn Lab Immunol 11:936-941, 2004.
131. Bone-Larson CL, Hogaboam CM, Steinhauser ML, Oliveira SHP, Lukacs NW, Strieter RM, Kunkel SL: Novel protective effects of stem cell factor in a murine model of acute septic peritonitis - dependence on MCP-1. Am J Pathol 157:1177-1186, 2000.
132. Ness TL, Hogaboam CM, Strieter RM, Kunkel SL: Immunomodulatory role of CXCR2 during experimental septic peritonitis. J Immunol 171:3775-3784, 2003.
133. Matsukawa A, Lukacs NW, Hogaboam CM, Knibbs RN, Bullard DC, Kunkel SL, Stoolman LM: Mice genetically lacking endothelial selectins are resistant to the lethality in septic peritonitis. Exp Mol Pathol 72:68-76, 2002.
134. Godshall CJ, Scott MJ, Peyton JC, Gardner SA, Cheadle WG: Genetic background determines susceptibility during murine septic peritonitis. J Surg Res 102:45-49, 2002.
135. Benjamim CF, Ferreira SH, Cunha FQ: Role of nitric oxide in the failure of neutrophil migration in sepsis. J Infect Dis 182:214-223, 2000.
136. Taylor FB Jr, Wada H, Kinasewitz G: Description of compensated and uncompensated disseminated intravascular coagulation (DIC) responses (non-overt and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli sepsis and in the human model of endotoxemia: toward a better definition of DIC. Crit Care Med 28:S12-S19, 2000.
137. Okamoto K, Takaki A, Takeda S, Katoh H, Ohsato K: Coagulopathy in disseminated intravascular coagulation due to abdominal sepsis - determination of prothrombin fragment 1 + 2 and other markers. Haemostasis 22:17-24, 1992.
138. Van Veen SQ, Cheung C, Meijers JC, van Gulik TM, Boermeester MA: Anticoagulant and anti-inflammatory effects after peritoneal lavage with antithrombin in experimental polymicrobial peritonitis. J Thromb Haemost 4(11):2343-2351, 2006
139. Schorr M, Siebeck M, Zugel N, Welcker K, Gippner-Steppert C, Czwienzek E, Groschler M, Jochum M: Antithrombin III and local serum application: adjuvant therapy in peritonitis. Eur J Clin Invest 30:359-366, 2000.
140. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, et al.: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29:894-903, 2003.
141. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G, Bernard GR: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31:834-840. 2003.
142. Van Veen SQ, Levi M, van Vliet AK, Florquin S, van Gulik TM, Boermeester MA: Peritoneal lavage with APC alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis. Crit Care Med 34(11):2799-2805, 2006.
143. Opal SM, Palardy JE, Parejo NA, Creasey AA: The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med 29:13-17, 2001.
144. Matyal R, Vin Y, Delude RL, Lee C, Creasey AA, Fink MP: Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock. Intensive Care Med 27:1274-1280, 2001.
145. Camerota AJ, Creasey AA, Patla V, Larkin VA, Fink MP: Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis. J Infect Dis 177:668-676, 1998.
146. Goldfarb RD, Glock D, Johnson K, Creasey AA, Carr C, McCarthy RJ, Matushek M, Akhter I, Trenholme G, Parrillo JE: Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock. Shock 10:258-264, 1998.
147. Abraham E, Reinhart K, Opal S, Demeyer I Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, et al.: Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290:238-247, 2003.
148. Tighe D, Moss R, Boghossian S, Heath MF, Chessum B, Bennett ED: Multiorgan damage resulting from experimental fecal peritonitis. Clin Sci 76:269-276, 1989.
149. Weijer S, Schoenmakers SH, Florquin S, Levi M, Vlasuk GP, Rote WE, Reitsma PH, Spek CA, van der Poll T: Inhibition of the tissue factor/factor VIIa pathway does not influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in mice. J Infect Dis 189:2308-2317, 2004.
150. Reddy RC, Chen GH, Newstead MW, Moore T, Zeng XY, Tateda K, Standiford TJ: Alveolar macrophage deactivation in murine septic peritonitis: role of interleukin 10. Infect Immun 69:1394-1401, 2001.
151. Huber-Lang MS, Younkin EM, Sarma JV, McGuire SR, Lu KT, Guo RF, Padgaonkar VA, Curnutte JT, Erickson R, Ward PA: Complement-induced impairment of innate immunity during sepsis. J Immunol 169:3223-3231, 2002.
152. Huber-Lang MS, Sarma JV, McGuire SR, Lu KT, Guo RF, Padgaonkar VA, Younkin EM, Laudes IJ, Riedemann NC, Younger JG, et al.: Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB J 15: 568-570, 2001.
153. Gerard C: Complement C5a in the sepsis syndrome-too much of a good thing? N Engl J Med 348:167-169, 2003.
154. Jochum M, Billing AG, Frohlich D, Schildberg FW, Machleidt W, Cheronis JC, Gippner-Steppert C, Fritz H: Proteolytic destruction of functional proteins by phagocytes in human peritonitis. Eur J Clin Invest 29:246-255, 1999.
155. Murphey ED, Lin CY, McGuire RW, Toliver-Kinsky T, Herndon DN, Sherwood ER: Diminished bacterial clearance is associated with decreased IL-12 and interferon-gamma production but a sustained proinflammatory response in a murine model of postseptic immunosuppression. Shock 21: 415-425, 2004.
156. Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaudry IH: Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/ IFN-gamma release while increasing IL-4/IL-10 production. J Surg Res 56:579-585, 1994.
157. Schein M, Wittmann DH, Holzheimer R, Condon RE: Hypothesis: compartmentalization of cytokines in intra-abdominal infection. Surgery 119:694-700, 1996.
158. Scheingraber S, Bauerfeind F, Bohme J, Dralle H: Limits of peritoneal cytokine measurements during abdominal lavage treatment for intra-abdominal sepsis. Am J Surg 181:301-308, 2001.
159. Zanetti G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, Lucas R, Glauser MP, Baumgartner JD: Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-alpha and to lipopolysaccharide. J Immunol 148:1890-1897, 1992.
160. Steinmuller M, Srivastava M, Kuziel WA, Christman JW, Seeger W, Welte T, Lohmeyer J, Maus UA: Endotoxin induced peritonitis elicits monocyte immigration into the lung: implications on alveolar space inflammatory responsiveness. Respir Res 7:30, 2006.
161. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL: Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 64:4733-4738, 1996.
162. Martineau L, Shek PN: Peritoneal cytokine concentrations and survival outcome in an experimental bacterial infusion model of peritonitis. Crit Care Med 28:788-794, 2000.
163. Wakefield CH, Barclay GR, Fearon KC, Goldie AS, Ross JA, Grant IS, Ramsay G, Howie JC: Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis. Scottish Sepsis Intervention Group. Br J Surg 85:818-825, 1998.
164. Riche FC, Cholley BP, Panis YH, Laisne MJ, Briard CG, Graulet AM, Gueris JL, Valleur PD: Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis. Crit Care Med 28:433-437, 2000.
165. Patel RT, Deen KI, Youngs D, Warwick J, Keighley MR: Interleukin 6 is a prognostic indicator of outcome in severe intra-abdominal sepsis. Br J Surg 81:1306-1308, 1994.
166. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D: Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun 67:6603-6610, 1999.
167. Stamme C, Bundschuh DS, Hartung T, Gebert U, Wollin L, Nusing R, Wendel A, Uhlig S: Temporal sequence of pulmonary and systemic inflammatory responses to graded polymicrobial peritonitis in mice. Infect Immun 67:5642-5650, 1999.
168. Emmanuilidis K, Weighardt H, Matevossian E, Heidecke CD, Ulm K, Bartels H, Siewert JR, Holzmann B: Differential regulation of systemic IL-18 and IL-12 release during postoperative sepsis: high serum IL-18 as an early predictive indicator of lethal outcome. Shock 18:301-305, 2002.
169. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL: Elevated levels of macrophage inflammatory protein 2 in severe murine peritonitis increase neutrophil recruitment and mortality. Infect Immun 65:3847-3851, 1997.
170. Sawyer RG, Rosenlof LK, Pruett TL: Interleukin-4 prevents mortality from acute but not chronic murine peritonitis and induces an accelerated tumor necrosis factor-alpha response. Eur Surg Res 28:119-123, 1996.
171. Alexander HR, Doherty GM, Venzon DJ, Merino MJ, Fraker DL, Norton JA: Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. Surgery 112:188-193, 1992.
172. Ganopolsky JG, Castellino FJ: A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model. Am J Pathol 165:1433-1446, 2004.